<SEC-DOCUMENT>0001564590-18-010927.txt : 20180504
<SEC-HEADER>0001564590-18-010927.hdr.sgml : 20180504
<ACCEPTANCE-DATETIME>20180504131256
ACCESSION NUMBER:		0001564590-18-010927
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180504
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180504
DATE AS OF CHANGE:		20180504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IRIDEX CORP
		CENTRAL INDEX KEY:			0001006045
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				770210467
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27598
		FILM NUMBER:		18807040

	BUSINESS ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6509404700

	MAIL ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>irix-8k_20180504.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irix-8k_20180504.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, DC 20549 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported) May 4, 2018 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX CORPORATION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.46%;"></td>
<td style="width:1.77%;"></td>
<td style="width:31.5%;"></td>
<td style="width:1.77%;"></td>
<td style="width:31.51%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0-27598</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">77-0210467</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer<br />Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1212 Terra Bella Avenue </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mountain View, California 94043 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code) </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(650) 940-4700 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:100%;">
<tr>
<td style="width:4.23%;"></td>
<td style="width:95.77%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:MS Mincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:MS Mincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:MS Mincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:MS Mincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td>
</tr>
</table></div>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="color:#000000;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (<font style="color:#000000;">&#167;</font>230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (<font style="color:#000000;">&#167;</font>240.12b-2 of this chapter).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company <font style="color:#000000;font-family:MS Mincho;">&#9744;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="color:#000000;font-family:MS Mincho;">&#9744;</font></p>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:101.17%;">
<tr>
<td style="width:13.39%;"></td>
<td style="width:87.78%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15pt;;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regulation FD Disclosure</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 4, 2018, IRIDEX Corporation (the &#8220;Company&#8221;) delivered the Company&#8217;s proxy solicitation materials for its 2018 annual meeting of stockholders to its stockholders of record as of April 16, 2018, which materials were accompanied by the President&#8217;s annual letter to stockholders attached as Exhibit 99.1 to this Current Report on Form 8-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this Current Report shall not be deemed "soliciting material" or "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that Section. The information in this Current report shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.<font style="font-weight:normal;margin-left:36pt;"></font>Financial Statements and Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:100%;">
<tr>
<td style="width:3.86%;"></td>
<td style="width:96.14%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.92%;"></td>
<td style="width:6.69%;"></td>
<td style="width:85.4%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="irix-ex991_7.htm"><font style="text-decoration:underline;">President&#8217;s annual letter to stockholders, dated as of May 4, 2018.</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:41.65%;">
<tr>
<td style="width:4.49%;"></td>
<td style="width:1.77%;"></td>
<td style="width:35.39%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11.5pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX CORPORATION</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ William M. Moore</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William M. Moore</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 4, 2018 </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>irix-ex991_7.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irix-ex991_7.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 4, 2018</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear IRIDEX Stockholder:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Throughout 2017 we continued to make significant progress in a transformation towards the $5 billion global glaucoma market with our MicroPulse&#174; technology. With this strategic change in the target market, also came an important business model shift to focus on driving volume and utilization over one-time capital equipment sales. This shift not only provides a significantly larger and more predictable revenue growth opportunity, but the potential to meaningfully expand margins and move towards sustainable profitability. While these transitions have come with some expected and unexpected hurdles, I am very proud of the advancement the IRIDEX team made throughout the year. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2017 Cyclo G6&#8482; Milestones and Results</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX entered 2017 with a strong base of clinical data, key opinion leader support, and early adopter customers for the Company&#8217;s G6 products. This gave us the confidence to make the necessary investments to realize this opportunity.&nbsp;&nbsp;We made significant progress towards this objective in 2017 by making substantial infrastructure enhancements, including:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.1%;text-indent:4.16%;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">Increased the U.S. sales organization by over 50%;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.1%;text-indent:4.16%;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">Established direct selling operations in Germany;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.1%;text-indent:4.16%;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">Launched the G6 in Germany and Japan, two core target countries;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.1%;text-indent:4.16%;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">Hired a new and expanded marketing team;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.1%;text-indent:4.16%;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">Significantly increased presence in glaucoma-oriented trade shows and digital media;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.1%;text-indent:4.16%;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">Added two key leadership roles:&nbsp;&nbsp;a VP of Clinical Affairs and VP of Regulatory Affairs; and</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:8.1%;text-indent:4.16%;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">Transitioned to a fully outsourced manufacturing model for our G6 systems and G6 probes, which improves production capacity and lowers costs</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, we shipped 377 G6 systems and approximately 32,000 G6 probes.&nbsp;&nbsp;These results reflect the impact of infrastructure enhancements, in particular in the second half of 2017 as G6 system shipments were almost double the first half of the year.&nbsp;&nbsp;Encouragingly, we also saw a significant increase in G6 probe utilization during the fourth quarter.&nbsp;&nbsp;We are acutely focused on improving G6 probe utilization.&nbsp;&nbsp;We believe this can be achieved by delivering improved customer service and customer training, which are key to realizing consistent positive treatment outcomes.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also realized significant growth in the volume of clinical data in support of G6, with 28 new studies of over 1,800 glaucoma patients presented at major society meetings in 2017.&nbsp;&nbsp;Lastly, we completed the development of several working prototypes of next-generation laser platforms that have the potential to improve product quality, reliability, and manufacturing cost.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Legacy Retina Business</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The legacy retina business, where we sell products primarily for the treatment of diabetic macular edema (DME) and other retinal diseases, maintained broad global support. In 2017, this segment continued to be hindered by our focus on the G6, competitive pricing pressure and our decision to voluntarily recall the TrueFocus LIO Premiere laser accessory, which is used in both medical and surgical retina procedures.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Looking Ahead</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have set two priorities for 2018 to guide our efforts:&nbsp;&nbsp;(1) to improve G6 probe utilization from our existing installed base, while continuing to expand the installed base across the globe; and (2) to introduce new products.&nbsp;&nbsp;In order to achieve this, we have set the following goals:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.26%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:2.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Build a clinical specialist team that will work with the sales team to improve customer service and training;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.26%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:2.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Obtain G6 regulatory clearance in China and Korea, two core target markets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.26%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:2.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Expand the direct salesforce in Germany;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.26%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:2.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Begin enrollment of IRIDEX-sponsored G6 clinical studies to further illustrate the mechanism of action, safety, efficacy, and value proposition of the G6;&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.26%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:2.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Realize the benefits of an increase in presentations of clinical studies by independent physicians throughout the year at major society meetings; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.26%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:2.83%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Complete the development and launch of a next generation platform.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In closing, 2017 was distinguished by meaningful progress on a transformation towards a glaucoma disposables-oriented business.&nbsp;&nbsp;We refined our strategy to best pursue this opportunity and are confident we have the right people and products to execute.&nbsp;&nbsp;We are excited to continue along the path towards long term, sustainable and profitable revenue growth.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I would like to thank my IRIDEX colleagues for their accomplishments in 2017 and to thank you personally for your support.&nbsp;&nbsp;We look forward to sharing future successes with you.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g20180504162214125864.jpg" title="" alt="" style="width:232px;height:69px;">Sincerely,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William M. Moore</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman &amp; Chief Executive Officer</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.49%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">This letter contains forward-looking statements, including with respect to our goals for 2018 and business strategy.&nbsp;&nbsp;Please see our Annual Report on Form 10-K for the year ended December 30, 2017 for important cautionary language regarding these statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g20180504162214125864.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20180504162214125864.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "? A4# 2(  A$! Q$!_\0
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MBB@ HHHH **** "BBB@ HHHH ***,YZ4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !112.X5<F@!:*KV.H07RLT$JMM8JQ5@<,#@CZBK%
M6"C)-1Q2QS+OC<,OM5#Q1I%]K^@7FD:;KMQI=S<6\D<&I6L:/+:N5($B"0,A
M92<C<I!QR#4?@_1=<T#PW::1XB\1OJ]]#"J7&I/;K";A@ -Y1>%)QDXXSG
MP  :]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S_P#\%$_V
MS[?]B7]G>\^)&E^&[CQ!XLUC4H="^'OA2VA9I-<URYRMK:#:"0&8;F..%#>U
M>^33B(XQEL9P.]?CS_P4P_:Y\9_&_P#:<^+WQ%^'.LQ7'PR_8X\!7^H^9YJB
M#4_B+/:S0V4<<FW_ %UF9,@ G]ZN".: /H'_ (-F/BO\3_CG_P $M]+^,_QC
MU^\U;Q-XH^('B;4]7U*\0*;B:?4YI7=5 "JA9VPJ@*!@    ?H37S;_P2+^
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MZA\0;ZZ_>7%QK&J6DAU$22 L9M@GEA#LQ)6)3TX !^U"'*J3Z4ZFQ@I&H/\
M=IU !11FC- !14<EQ'$=K-S4%]KNDZ5;F\U74(;6$'!EN)0B@^F3B@"WD>M%
M>?S_ +4/[.UKX[A^&,_QK\,KXBNKB."WT3^V(?M,DDF-BK'NR6;(P,<YKT#-
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5A?$3QOX:^&O@+6OB-XRU5;+1] TN?4=5O),X@MH8S)(_X(K&
MMVOS_P#^"^_QF\67/[-OAO\ X)^?!_5)K3X@?M-^*[;P7X?U"-OW>FV)FC?4
M+J7'S;/LP>+"\YFST!H \*_9>^,=S\"_V"OVDO\ @O;X\MVO?&OQ<AO[_P !
M6]SB5['28I&LM#T[Y,[%>?R3)CH2&(P*^V_^"47[(5O^QQ^Q3X-^'FI27%QX
MHUFU3Q%X^U2ZF9Y;_7KU%FO9VW\KF3Y0O90!VS7RW^T!\+/AU\0?VI?@%_P1
M0^"GARX/PZ^&MK9>,_BYH]G&/L,>F66Y["SG<G<3/>+%(4Z.C'.#C'Z=0JJQ
M+Q_"* ([F9HE4J,LQPJ^O'2OFG]A?]N7Q1^V)\:?V@/##> ETOPS\*/B=_PB
M'AW5/,W-JCV\"B\EW#Y2%GW;<'.QT!YKI/\ @I1^UU!^PU^Q5X\_:8@TF/4M
M2\/Z.W]@Z7(Q O\ 492(K:#CYB&E9<A?FP&Q6'_P27_9YU/]G3]@+X>^$_%M
MO_Q5.M:9)XD\:7+Q[9)]:U.5K^\9N >)9V0 _=6-5_A% 'TM1110 C$XR*^,
M/^"SW[2GB/X?? _PY^R/\'K^:'XE?M#^)HO _A&YM9E5]+@G^:^U)N^R&V#C
MC_EI)'T&2/LJZ(\@[I-FWYBV<8YK\W_V2;R+]O7_ (+3_%S]K'6-)^W^#?V?
M]#A\!?#.ZD<R6O\ :MP[R:EJ-O\ PF0HOV<LI.$]"U 'L'[1'A"7]@3_ ()G
MV?[*_P"Q]H%W)KUWI-OX&^&MO#/^_34-1?[/_:#.<X\DS37;L1@>6V<"OI?X
M*_#ZP^$OPM\._"_299)+?P_H=K81RR'<\GE1JI=C_>)R3[FOE+X5:P/V[?\
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M#]@CXR^'+?6+KX[?#>]\?ZQXHCLTA;3M>LY46XTM6',\,,,T"\X*,XV_*QH
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M&#BOT>_:!^*FF?!+X*^+_C!K^L6^FV/A?PS>ZK=7MX<1PK!!)+N;V^4<#D]
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M4?C[]I/]D_X]R>%V^*FI:=>>//#>M:6+ZSEN((S"]Y;*2/)G>(1+W4^7R.E
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M$I2V@<CHD2LX4#CYR>] 'T= VZ+(K\X?CE^R%_P4W_9:_;H^(/[4G_!-#1O
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MZ=XLM?A7_P %2?B1IK:E&C>%8;ZWAEBT>9[[SYSP-TJ^3F%%)^7.>PK1T_\
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M!;X)>"K'P]X:T&QCM=-TO3X=B(J@#>W=W8C<SG+,Q)8DY-=M0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%%  1D8-1K;QJ,"I**  # Q
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
